Check out the companies making headlines in midday trading. Intel — The struggling chip stock bounced into year-end, rising close to 1.2% in midday trading. Intel has plunged more than 60% in 2024, making the stock poised to see its worst year on record and be the second worst performer in the S & P 500 . Nvidia — The artificial intelligence giant and retail investor favorite shed 1.3% as traders took profits as the trading year wraps up. With a rally of more than 170%, Nvidia is poised to be the third best performer in the S & P 500 for 2024. Sangamo Therapeutics – Shares tumbled 54% after the genomic medicine company said partner Pfizer terminated a license and development agreement for a gene therapy for hemophilia A. Sangamo retained rights to the product. Biohaven — The biopharmaceutical stock popped nearly 2% after director John Childs disclosed a purchase of 29,000 shares. Childs now owns around 6.5 million shares. Nutriband – Shares jumped more than 8% after Nutriband said it expects an expedited review process for its abuse-deterrent opioid patch called AVERSA Fentanyl, which could position the company to achieve regulatory approval before the end of 2025. This comes after Nutriband announced last week that it extended its Chinese patent to Macao for the technology. Zivo Bioscience — Shares rose neary 3% after Mark Strome, an investor who owns 10% of the biotech research and development company, bought 75,000 shares. — CNBC’s Sean Conlon, Yun Li and Pia SIngh contributed reporting
INTC, BHVN, NVDA and more